ResMed Inc (RMD)

NYSE
Currency in USD
236.10
+21.66(+10.10%)
Closed·
Pre Market
235.71-0.39(-0.17%)
·
RMD Scorecard
Full Analysis
Has raised its dividend for 13 consecutive years
Fair Value
Day's Range
227.40239.66
52 wk Range
179.42263.05
Key Statistics
Edit
Prev. Close
236.1
Open
233.19
Day's Range
227.4-239.66
52 wk Range
179.42-263.05
Volume
2.26M
Average Volume (3m)
1.14M
1-Year Change
28.47%
Book Value / Share
35.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
265.42
Upside
+12.42%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings upwards for the upcoming period
Show more

ResMed Inc Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed Inc SWOT Analysis


Sleep Tech Dominance
ResMed's strong market position in sleep and respiratory care, driven by innovative products and consistent double-digit revenue growth in key segments
GLP-1 Drug Challenge
Explore the potential impact of emerging GLP-1 drugs on ResMed's core CPAP device business and the company's strategies to maintain growth
Analyst Projections
Average price target of $236, with estimates ranging from $180 to $280, reflecting varied views on ResMed's future performance
Beyond Sleep Apnea
Delve into ResMed's expansion into new markets like insomnia and COPD, leveraging AI and wearable technology to diversify revenue streams
Read full SWOT analysis

ResMed Inc Earnings Call Summary for Q3/2025

  • ResMed Q3 FY2025 revenue beat forecast at $1.3B, up 8% YoY; EPS slightly missed at $2.37
  • Gross margin improved to 59.9%, net income up 11%; stock rose 3.53% after-hours to $222
  • CEO highlighted innovation focus and proactive market expansion efforts
  • Q4 gross margins expected to remain consistent; FY2025 effective tax rate estimated at 19-21%
  • Company exploring M&A opportunities, expanding patient diagnostic and treatment funnel
Last Updated: 24/04/2025, 04:08 pm
Read Full Transcript

Compare RMD to Peers and Sector

Metrics to compare
RMD
Peers
Sector
Relationship
P/E Ratio
26.4x−2.1x−0.5x
PEG Ratio
0.710.110.00
Price/Book
6.2x2.0x2.6x
Price / LTM Sales
6.9x3.6x2.9x
Upside (Analyst Target)
13.9%114.6%58.9%
Fair Value Upside
Unlock−9.4%8.0%Unlock

Analyst Ratings

12 Buy
6 Hold
1 Sell
Ratings:
19 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 265.42
(+12.42% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.94%
Dividend Yield
0.99%
Industry Median 0.71%
Annualised payout
2.12
Paid quarterly
5-Years Growth
+5.58%
Growth Streak

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
2.37 / 2.39
Revenue / Forecast
1.30B / 1.29B
EPS Revisions
Last 90 days

People Also Watch

162.13
TXN
+6.56%
152.30
ZTS
+0.92%
126.04
DHI
+1.00%
265.19
PGR
+0.06%
33.19
CMCSA
-3.71%

FAQ

What Is the ResMed (RMD) Stock Price Today?

The ResMed stock price today is 236.10

What Stock Exchange Does ResMed Trade On?

ResMed is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for ResMed?

The stock symbol for ResMed is "RMD."

Does ResMed Pay Dividends? What’s The Current Dividend Yield?

The ResMed dividend yield is 0.90%.

What Is the ResMed Market Cap?

As of today, ResMed market cap is 34.62B.

What is ResMed Earnings Per Share?

The ResMed EPS is 8.94.

What Is the Next ResMed Earnings Date?

ResMed will release its next earnings report on 30 July 2025.

From a Technical Analysis Perspective, Is RMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.